AWM
BLRX

Apollon Wealth Management’s BioLineRX BLRX Stock Holding History

Apollon Wealth Management’s Portfolio BLRX Stock Details BLRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q4 		– Sell
-1,220
Closed -$45K – 862
2022
Q3 		$45K Buy
+1,220
New +$69.6K ﹤0.01% 784
2022
Q2 		– Sell
-1,410
Closed -$96K – 758
2022
Q1 		$96K Buy
+1,410
New +$98.2K 0.01% 726

Other funds holding BLRX

ACM
Altium Capital Management New York $42M AUM
SM
Sabby Management Miami Beach, Florida $45.1M AUM 74.25% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
LPL Financial
LPL Financial San Diego, California $377B AUM 19.32% 1-Year Est. Return
AWS
Atria Wealth Solutions New York $4.42B AUM 16.4% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
GWM
Geneos Wealth Management Englewood, Colorado $4.31B AUM 18.36% 1-Year Est. Return
CCB
Cutter & Co Brokerage Ballwin, Missouri $423M AUM 15.02% 1-Year Est. Return
BAM
Belpointe Asset Management Reno, Nevada $2.74B AUM 20.71% 1-Year Est. Return

Apollon Wealth Management's BLRX Position: Q4 2022 in Review

Apollon Wealth Management sold out of BioLineRX (BLRX) in Q4 2022, closing a stake of 1,220 shares — an estimated $45K sold.

Apollon Wealth Management first reported a position in BLRX in Q1 2022 and held it in 2 quarters. The position peaked at $96K in Q1 2022. 18 funds tracked by Wall St. Rank hold BLRX as of Q4 2022.

  • Apollon Wealth Management reported no remaining BioLineRX position as of Q4 2022 after selling out during the quarter.
  • Apollon Wealth Management sold 1,220 BioLineRX shares in Q4 2022, an estimated $45K.
  • Apollon Wealth Management first reported a position in BioLineRX in Q1 2022 and held it in 2 quarters.
  • Apollon Wealth Management's BioLineRX position peaked at $96K in Q1 2022.
  • 18 funds tracked by Wall St. Rank held BioLineRX as of Q4 2022.

Based on Apollon Wealth Management's 13F filing for Q4 2022, filed 15 Feb 2023.